Specimen Collection Manual and Test Catalog
SOLUBLE FIBRIN MONOMERS
Geisinger Epic Procedure Code: LAB3072 Geisinger Epic ID: 7159Platelet-poor plasma
1 mL
This test is offered at a limited number of performing laboratories and may only be collected and performed at testing sites (see below).
- If the patient’s hematocrit (HCT) is >55%, the volume of anticoagulant in the tube must be adjusted. Contact a performing location for sodium citrate adjusted tubes or instruction for how to adjust the sodium citrate.
- When possible, use fresh venipuncture.
- Avoid prolong tourniquet time (< 1 minute) and hemolysis during collection as this will alter results.
- If indwelling catheter or butterfly collection device must be used, draw sample from a non-heparinized lumen or flush the line with 5 mL of saline and discard/use first 5-10 mL of blood for other purposes
- Tubes should be >90% filled.
- Immediately mix gently after collection by inverting the tube end over end 5 to 6 times. Avoid vigorous mixing or additional inversion. Observe for the presence of clots and recollect if observed.
- Immediately transport at room temperature to Coagulation Laboratory after collection.
Centrifuge within 60 minutes at designated speed and time to obtain platelet-poor plasma (<10,000/µL). Using a plastic pipette, carefully remove plasma from cells, avoiding platelet/buffy layer by leaving a thin layer of plasma on top the cells. Transfer centrifuged plasma into clearly labeled polypropylene tubes.
Room temperature
Room temperature: 2 hours
Clotted, hemolyzed, improperly filled tubes, improper anticoagulant ratio (HCT >55% and citrate not adjusted), refrigerated or frozen specimens, or stability exceeded.
Negative
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.
Fibrin Monomer, Soluble Fibrin Monomers, SFM
The assay can assist in diagnosing disseminated intravascular coagulation (DIC). Fibrin monomers are produced as soluble fibrinogen is transformed into insoluble fibrin clot. This intermediate product can form soluble complexes with fibrinogen or fibrinogen degradation products when thrombin levels are low (commonly observed in patients with DIC). These soluble complexes are then visualized using RBC agglutination. DIC is a clinical diagnosis, and no single test should be used to diagnose DIC. This assay should be correlated with other DIC tests (PT, APTT, D-Dimer, and platelet count). In neonates, interpret samples with caution, as the results are often positive, due to difficulty in sample collection.